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Abstract 
 
ALS is a disease targeting motoneurons (MN). In the SOD1 mouse model of ALS, an axonal die-
back process is initiated during the pre-symptomatic stage where MN axons withdraw from 
target muscle. We have used facial nerve axotomy, which resembles the axonal die-back 
response, in pre-symptomatic SOD1 mice to investigate aspects of the disease. Apoptotic and 
pro-inflammatory gene expression is upregulated in pre-symptomatic SOD1 axotomized facial 
nuclei in addition to significant SOD1 MN death. Disease progression in symptomatic SOD1 
facial nuclei resembles the molecular response initiated by axotomy. MN survival levels in 
symptomatic SOD1 and axotomized, presymptomatic SOD1 facial nuclei are similar. Therefore, 
facial nerve axotomy produces a disease onset-like response. The current study used behavioral 
testing to assess motor function, and revealed two groups of SOD1 mice with differing rates of 
symptomatic disease progression. The slow progression group had significantly less motor 
impairments compared to the fast progression group, but no difference in symptom onset was 
seen. Fast progression group showed higher mRNA levels for genes related to axonal injury. 
Symptomatic severity in SOD1 mice correlates to the cellular and molecular responses to axonal 
injury. Therefore, research using treatments to slow disease or extend 
